Instruction for use: Naramig

Dosage form: Coated tablets

Active substance: Naratriptan*

ATX

N02CC02 Naratriptan

Pharmacological group:

Serotonergic agents

The nosological classification (ICD-10)

G43 Migraine: The pain of migraine; Migraine; hemiplegic migraine; Migraine headache; A migraine attack; Continuous headache; hemicranias

G43.0 Migraine without aura [simple migraine]: Migraine without aura

G43.1 Migraine with aura [classic migraine]: Basilar migraine; Migraine with aura

Composition and release form

Tablets, coated with a coating.

Naratriptan hydrochloride 2.5 mg

In the blister 2, 4 or 6 pcs .; In the box 1 blister.

Pharmachologic effect

Mode of action - antimigraine.

Selectively turned on 5-hydroxytryptamine (5-HT1B / 1D) receptors causes contraction of intracranial vessels.

Pharmacokinetics

Quickly absorbed from the digestive tract. Cmax is achieved within 2-3 hours after ingestion and is about 2.5 mg 8.3 ng / ml in females and 5.4 ng / ml in males. Bioavailability - 74% in women and 63% in men. The volume of distribution is 170 liters. Binding to plasma proteins is low (29%). Passes histohematological barriers, incl. GEB and is determined in tissues. T1 / 2 on average -. 6 hours after the Middle Cl / in the introduction - 470 ml / min in males and 380 ml / min in females. Kidney Cl is the same in men and women (220 ml / min). Excreted mainly in urine, 50% of the dose - unchanged, 30% - as inactive metabolites.

Indication of the drug Naramig

Migraine with aura and without it (relief of seizures).

Contraindications

Hypersensitivity (including sulfonamide), myocardial infarction, coronary artery disease, peripheral vascular disease, stroke, cerebrovascular disease, uncontrolled hypertension, expressed as the liver and kidneys, hemiplegic, basilar migraine or oftalmoplegicheskaya form, simultaneous assignment al. Agonists 5-HT1 receptors; elderly (over 65 years) and children or youth (under 18 years) age, pregnancy, breastfeeding (must stop).

Side effects

Pain, tingling sensation, heat, severity, compression or compression, nausea, vomiting.

Interaction

Incompatible with preparations containing ergotamine and its derivatives.

Dosing and Administration

Inside (only with an attack). Adults (aged 18-65 years) the recommended single dose - 2.5 mg. If after the initial reduction the symptoms appear again, a second dose can be prescribed (with an interval of at least 4 hours); The daily dose should not exceed 5 mg, in patients with renal and hepatic insufficiency - 2.5 mg.

Storage conditions of the drug Naramig

At temperatures not higher than 30 ° C.

Keep out of the reach of children.

Shelf life of the drug Naramig

3 years.

Do not use after the expiry date printed on the package.